The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
about
Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledgeSafety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Cardiac imaging for the assessment of patients being evaluated for kidney or liver transplantation.Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies.Regadenoson stress for myocardial perfusion imaging.Stress SPECT Myocardial Perfusion Imaging in End-Stage Renal Disease.Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review.The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease.Diagnostic and prognostic significance of ischemic electrocardiographic changes with regadenoson-stress myocardial perfusion imaging.The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT.Late aminophylline reversal of regadenoson stress testing in patients with end stage renal disease.The impact of regimented aminophylline use on extracardiac radioisotope activity in patients undergoing regadenoson stress SPECT myocardial perfusion imaging: a substudy of the ASSUAGE trial.Use of regadenoson in end-stage renal disease.Regadenoson for myocardial perfusion imaging: Is it safe?Aminophylline and caffeine for reversal of adverse symptoms associated with regadenoson SPECT MPI.The significance of post-stress decrease in left ventricular ejection fraction in patients undergoing regadenoson stress gated SPECT myocardial perfusion imaging.
P2860
Q26829779-289B34EB-985F-4C3D-B50C-C360C7947DA2Q37596745-659659BE-5260-470B-8DC4-4A8B40B6F480Q38258031-F11C0ADD-AE14-412F-87B0-7923DFE96030Q38480969-80F89472-C859-4FB4-98AC-FCA010FE2921Q38660349-FE3C065B-7472-4AA9-8089-553EFCBA7163Q38661588-1F8F828F-D572-4BBF-9CFC-F4B761ED6954Q38707736-4FF986BC-3AD7-4BE8-93CD-0515CF888A78Q40306377-A6C42570-65E0-42E3-83DF-1A63FDAA35E3Q40622248-4A52A767-0F4D-41DB-9539-C2C34B1E5580Q41021332-F63D7BAD-C802-4EE2-B725-A49EB3BFB0F4Q41139048-B7E03A32-A174-4038-83B2-5B69FC15E982Q41932164-2B3CDCA9-0630-401E-B208-06904743EE9AQ44485428-C89495E8-7801-4703-AB4E-7197ED303D42Q44634568-3F7FE13B-254A-4750-902B-C956F2783C5CQ48271472-E9B80F4F-3103-4397-88CF-B692470FFE59Q50865881-DFEDEEB7-D0EF-494F-876F-87959AAC4D0EQ53516893-94E10F3D-D3D0-498B-AC24-633798D77C25
P2860
The safety and tolerability of regadenoson in patients with end-stage renal disease: the first prospective evaluation.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The safety and tolerability of ...... first prospective evaluation.
@en
The safety and tolerability of ...... first prospective evaluation.
@nl
type
label
The safety and tolerability of ...... first prospective evaluation.
@en
The safety and tolerability of ...... first prospective evaluation.
@nl
prefLabel
The safety and tolerability of ...... first prospective evaluation.
@en
The safety and tolerability of ...... first prospective evaluation.
@nl
P2093
P2860
P1476
The safety and tolerability of ...... first prospective evaluation.
@en
P2093
Ammar Alqaid
Maria Octavia Rangel
Marwan Wassouf
Raysa Morales Demori
Rizcallah Dick
P2860
P2888
P304
P356
10.1007/S12350-012-9654-2
P50
P577
2012-12-13T00:00:00Z